BVS vs. NUTX

Last updated Apr 1, 2026

Compare and contrast key facts about Bioventus Inc. (BVS) and Nutex Health Inc (NUTX).

Performance

BVS vs. NUTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bioventus Inc. (BVS) and Nutex Health Inc (NUTX). The values are adjusted to include any dividend payments, if applicable.

BVS vs. NUTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
BVS Bioventus Inc.	22.72%	-29.14%	99.24%	101.92%	-80.36%
NUTX Nutex Health Inc	-42.27%	419.47%	17.37%	-90.53%	-95.25%

Fundamentals

EPS BVS : $0.33 NUTX : $14.78
PE Ratio BVS : 27.62 NUTX : 6.43
PEG Ratio BVS : 0.23 NUTX : 0.05
PS Ratio BVS : 1.11 NUTX : 0.47
Total Revenue (TTM) BVS : $568.09M NUTX : $875.26M
Gross Profit (TTM) BVS : $386.76M NUTX : $444.28M
EBITDA (TTM) BVS : $53.38M NUTX : $274.31M

Returns By Period

In the year-to-date period, BVS achieves a 22.72% return, which is significantly higher than NUTX's -42.27% return.

BVS

• 1D: 1.90%
• 1M: 3.99%
• YTD: 22.72%
• 6M: 36.47%
• 1Y: -0.22%
• 3Y*: 104.34%
• 5Y*: -9.73%
• 10Y*: —

NUTX

• 1D: 4.55%
• 1M: -13.96%
• YTD: -42.27%
• 6M: -8.01%
• 1Y: 102.08%
• 3Y*: -14.40%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BVS vs. NUTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BVS

BVS Risk / Return Rank: 40
BVS Sharpe Ratio Rank: 40
BVS Sortino Ratio Rank: 39
BVS Omega Ratio Rank: 38
BVS Calmar Ratio Rank: 42
BVS Martin Ratio Rank: 42

NUTX

NUTX Risk / Return Rank: 72
NUTX Sharpe Ratio Rank: 72
NUTX Sortino Ratio Rank: 79
NUTX Omega Ratio Rank: 74
NUTX Calmar Ratio Rank: 72
NUTX Martin Ratio Rank: 64

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BVS vs. NUTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bioventus Inc. (BVS) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BVS	NUTX	Difference
Sharpe ratio Return per unit of total volatility	-0.00	0.88	-0.89
Sortino ratio Return per unit of downside risk	0.38	1.99	-1.60
Omega ratio Gain probability vs. loss probability	1.05	1.24	-0.19
Calmar ratio Return relative to maximum drawdown	0.03	1.54	-1.51
Martin ratio Return relative to average drawdown	0.05	2.40	-2.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BVS vs. NUTX - Sharpe Ratio Comparison

The current BVS Sharpe Ratio is -0.00, which is lower than the NUTX Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of BVS and NUTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BVS	NUTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.00	0.88	-0.89
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.12	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.17	-0.48	+0.31

Correlation

The correlation between BVS and NUTX is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BVS vs. NUTX - Dividend Comparison

Neither BVS nor NUTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BVS vs. NUTX - Drawdown Comparison

The maximum BVS drawdown since its inception was -95.18%, roughly equal to the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for BVS and NUTX.

Drawdown Indicators

	BVS	NUTX	Difference
Max Drawdown Largest peak-to-trough decline	-95.18%	-99.93%	+4.75%
Max Drawdown (1Y) Largest decline over 1 year	-35.44%	-54.34%	+18.90%
Max Drawdown (5Y) Largest decline over 5 years	-95.07%	—	—
Current Drawdown Current decline from peak	-52.47%	-98.42%	+45.95%
Average Drawdown Average peak-to-trough decline	-56.63%	-97.24%	+40.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.64%	34.90%	-11.26%

Volatility

BVS vs. NUTX - Volatility Comparison

The current volatility for Bioventus Inc. (BVS) is 14.96%, while Nutex Health Inc (NUTX) has a volatility of 24.94%. This indicates that BVS experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BVS	NUTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.96%	24.94%	-9.98%
Volatility (6M) Calculated over the trailing 6-month period	32.61%	73.87%	-41.26%
Volatility (1Y) Calculated over the trailing 1-year period	51.11%	116.41%	-65.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.73%	135.16%	-54.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.79%	135.16%	-54.37%

Financials

BVS vs. NUTX - Profitability Comparison

The chart below illustrates the profitability comparison between Bioventus Inc. and Nutex Health Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bioventus Inc. reported a gross profit of 108.78M and revenue of 157.90M. Therefore, the gross margin over that period was 68.9%.

NUTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a gross profit of 46.14M and revenue of 151.68M. Therefore, the gross margin over that period was 30.4%.

BVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bioventus Inc. reported an operating income of 19.49M and revenue of 157.90M, resulting in an operating margin of 12.3%.

NUTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported an operating income of 39.37M and revenue of 151.68M, resulting in an operating margin of 26.0%.

BVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bioventus Inc. reported a net income of 14.76M and revenue of 157.90M, resulting in a net margin of 9.3%.

NUTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a net income of 11.83M and revenue of 151.68M, resulting in a net margin of 7.8%.